Please try another search
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has a collaborative research program with Patrys Limited and The University of Sydney. Imagion Biosystems Limited was incorporated in 2016 and is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Michael John Harsh | 70 | 2017 | Non-Executive Director |
Mark Gerland Van Asten | - | 2016 | Non Executive Director |
John Hazle | - | 2018 | Chairman of Scientific Advisory Board |
David Gerald Ludvigson | 73 | 2017 | Non Executive Director |
Robert Romeo Proulx | 66 | 2015 | Executive Chairman |
Andrew M. Scott | - | 2019 | Member of Scientific Advisory Board |
Lisa Horvath | - | 2019 | Member of Scientific Advisory Board |
Robert Ivkov | - | 2019 | Member of Scientific Advisory Board |
Paul C. Grint | 66 | 2019 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review